Table 3.

Summary of research studies on ethnoracial differences in LB dementia

Category	Summary of current research on ethnic and racial differences
Prevalence	DLB prevalence higher for immigrants from North Africa and Latin America than natives in Belgium [59], but not different across ethnoracial groups in the United States [61].
Diagnosis and clinical features	In the NACC, clinical diagnostic accuracy is lower in people identifying as Black compared to people identifying as White [69]. Despite more advanced LB pathology stage, diagnosis of LB disease is less common for people identifying as Black compared to people identifying as Hispanic or White [68]. Compared to people identifying as White, higher rates of diabetes, hypertension, depression, female sex, single status, living alone, as well as lower education levels and worse performance on various cognitive tests were observed in people identifying as Black or Hispanic that were clinically diagnosed with MCI or dementia due to a LB disorder [67].
Progression	No significant differences for progression and mortality after accounting for age at onset, sex, education and the level of underlying LB and AD pathology [68].
Neuropathology	Compared to people identifying as White, co-pathology rates (e.g. vascular, AD, frontotemporal lobar degeneration) may be higher in people not identifying as White [82] [85]. Regional pathology burden and clinicopathological correlations can differ; higher LB count in the anterior cingulate cortex, stronger association between LB pathology and parkinsonism in people identifying as Black compared to people identifying as White [86].
Treatment and clinical trials	Antiparkinsonian, antidepressant and Alzheimer’s drug use may be higher in people identifying as White compared to people identifying as Black non-Hispanic or Hispanic [67]. More than 9 out of 10 people participating in clinical trials identify as non-Hispanic White (see Table 2).